Cost effectiveness of recombinant factor VIIa for treatment of intracerebral hemorrhage
نویسندگان
چکیده
منابع مشابه
Cost effectiveness of recombinant factor VIIa for treatment of intracerebral hemorrhage
BACKGROUND Phase I/II placebo-controlled clinical trials of recombinant Factor VIIa (rFVIIa) suggested that administration of rFVIIa within 4 hours after onset of intracerebral hemorrhage (ICH) is safe, limits ICH growth, and improves outcomes. We sought to determine the cost-effectiveness of rFVIIa for acute ICH treatment, using published Phase II data. We hypothesized that rFVIIa would have a...
متن کاملPotential applicability of recombinant factor VIIa for intracerebral hemorrhage.
BACKGROUND AND PURPOSE To date, there are no proven, effective treatments for intracerebral hemorrhage (ICH) beyond supportive medical care. A recent randomized, blinded, placebo-controlled trial of recombinant factor VIIa (rFVIIa) administered intravenously within 4 hours of ICH onset reported a reduction in morbidity and mortality compared with placebo. We sought to determine the potential ap...
متن کاملRecombinant Human Coagulation Factor VIIa for Intracerebral Hemorrhage.
with expanding intracranial bleeds associated with neurologic deterioration, or where urgent surgical intervention is indicated. Often, a single dose of 40 microg/Kg dramatically corrects the coagulopathy in minutes, allowing stabilization of clot expansion and safe neurosurgical intervention, while fresh frozen plasma, vitamin K and other products are administered for subacute maintenance of n...
متن کاملCost-effectiveness of recombinant activated factor VII in the treatment of intracerebral hemorrhage.
BACKGROUND AND PURPOSE Intracerebral hemorrhage (ICH) is among the most costly and debilitating forms of stroke. Results from a recent Phase IIb clinical trial demonstrate that administration of recombinant activated factor VII (rFVIIa) reduces ICH mortality and improves functional outcome. In the current analysis, we examine the cost-effectiveness of early treatment with rFVIIa for ICH in the ...
متن کاملHemostatic treatment in the early stage of intracerebral hemorrhage: the recombinant factor VIIa experience.
The treatment of intracerebral hemorrhage (ICH) has been a largely neglected item. In contrast to literally dozens of clinical trials of treatment of ischemic stroke, only a handful have addressed treatment of ICH with either medical (steroids,1 osmotic diuretics2) or surgical3 interventions. The medical intervention trials, primarily aimed at reducing brain edema surrounding the ICH, have show...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: BMC Neurology
سال: 2008
ISSN: 1471-2377
DOI: 10.1186/1471-2377-8-17